Press Releases

Disagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription

Immunexpress.com

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…

Read More

Immunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis

Immunexpress.com

Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress’ SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected of sepsis. DRIVe (Division of…

Read More

European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics

Immunexpress.com

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’ from both the U.S. Patent…

Read More

Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

Immunexpress.com

The allowance complements the Company’s growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, “Validating biomarker measurement,” which relates to methods…

Read More

Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality

Immunexpress.com

SEATTLE, July 10, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company’s Executive Team as Vice President of Regulatory Affairs and Quality. “Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences industry,” Rolland D. Carlson, PhD, President…

Read More

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

Immunexpress.com

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Read More

SeptiCyte™ LAB Differentiates Sepsis from Infection-Negative Systemic Inflammation in Critically Ill Children

Immunexpress.com

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability…

Read More

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

Immunexpress.com

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…

Read More

Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients

Immunexpress.com

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation…

Read More

Four-Biomarker Signature Differentiates Viral and Non-Viral Causes of Systemic Inflammation

Immunexpress.com

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker blood signature to discriminate viral…

Read More